Effect of Oxybutynin on Opioid Use After Urologic Surgery in Children
A Randomized Double-Blind Placebo-Controlled Trial Evaluating the Opioid-Sparing Effect of Preoperative Oxybutynin in Children Undergoing Urologic Reconstruction
The goal of this clinical trial is to determine whether giving oxybutynin before urologic reconstruction surgery reduces the amount of opioid pain medication needed in children. Oxybutynin is a medication that helps reduce bladder spasms, which can cause pain and discomfort after surgery.
The main question this study aims to answer is:
Does giving oxybutynin before surgery reduce the amount of opioid pain medication children need during the first 6 hours after surgery?
Researchers will compare oxybutynin with a placebo (a tablet containing no active medication) to see whether oxybutynin reduces opioid use after surgery.
研究概览
详细说明
Background
Children undergoing pediatric urologic reconstruction, such as pyeloplasty and hypospadias repair, frequently require urinary drainage via ureteral stent and/or urethral catheter. These tools cause the bladder to contract involuntarily, mediated by muscarinic receptors (i.e., bladder spasms). This leads to increased catheter-related bladder discomfort (CRBD), bladder spasm-associated pain and postoperative opioid use.
Oxybutynin, an antimuscarinic agent, reduces the occurrence of bladder spasms and thus the number and severity of CRBD events and bladder spasm-related pain. This reduction in discomfort/pain may contribute to decreased postoperative opioid use, as suggested by retrospective pediatric data.
Postoperative management of urologic reconstruction surgeries includes PRN administration of opioids and oxybutynin to treat bladder spasm-related discomfort/pain according to institutional practice and prior pediatric urology literature. Oxybutynin takes 1 hour to reach its maximal plasma concentration, during which time significant bladder spasm-related symptoms may already be present when the child is awake. However, opioids such as morphine achieve their maximal effects within 10 minutes. Because opioids are much faster-acting than oxybutynin, this may increase the likelihood of concomitant administration when the child is awake with discomfort/pain. We are therefore considering using oxybutynin preoperatively, rather than just postoperatively PRN, since its plasma concentration will already be maximal or near-maximal upon waking, which may lead to less CRBD, bladder spasm-related pain, and postoperative opioid use.
This study aims to reduce the use of opioids to treat pediatric patients undergoing urologic reconstruction. Opioids carry significant side effects that include nausea, vomiting, respiratory depression, addiction, urinary retention, tolerance, and constipation. Combined with the ongoing opioid epidemic, there is an increased effort among caregivers, including nurses and physicians, to find other means to reduce pain in pediatric patients.
Opioid therapy has also been shown not to be effective in treating bladder spasm-related symptoms (e.g., CRBD, bladder spasm-related pain). As opposed to opioids, oxybutynin directly targets bladder spasm-associated symptoms, and may reduce the severity of side effects. Side effects of oxybutynin include dry mouth, constipation, dizziness, urinary retention, and blurry vision.
Emerging pediatric urology data suggest that a single preoperative dose may reduce early postoperative opioid requirements. However, current evidence is retrospective and non-randomized. There is no high-quality randomized pediatric study evaluating the opioid sparing effects of preoperative oxybutynin administration in pediatric patients undergoing urologic reconstruction.
Study Need, Importance, and Hypothesis
Urologic reconstruction surgeries requiring a stent and/or catheter can be associated with significant CRBD, bladder-spasm associated pain and morbidity. With the growing recognition of the need to decrease opioid medication, our primary objective is to assess whether the administration of preoperative oxybutynin reduces opioid use. We hypothesize that preoperative oxybutynin reduces early postoperative opioid use in children undergoing pyeloplasty or hypospadias repair.
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:Hayder Al-Kazzaz
- 电话号码:403-955-7757
- 邮箱:hayder.alkazzaz@ucalgary.ca
研究联系人备份
- 姓名:Bryce Weber, MD
- 电话号码:403-955-2776
- 邮箱:bryce.weber@albertahealthservices.ca
学习地点
-
-
Alberta
-
Calgary、Alberta、加拿大、T2B6A8
- Alberta Children's Hospital
-
首席研究员:
- Bryce Weber
-
接触:
- Hayder Al-Kazzaz
- 电话号码:403-955-7757
- 邮箱:hayder.alkazzaz@ucalgary.ca
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- All children aged 0 to 17 years old admitted for pyeloplasty or hypospadias repair. There is no minimum weight for inclusion
Exclusion Criteria:
- Contraindications to anticholinergic medications
- Urinary retention disorders
- Gastrointestinal obstruction/ileus
- Contraindications to anesthetic protocol, including 1) allergy to any anesthetic medication in protocol, 2) refusal of regional technique, 3) contraindications to ketorolac (i.e., recent GI bleed, recent intracranial bleed, renal dysfunction, acute kidney injury)
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Preoperative Oxybutynin
Participants will receive oxybutynin 0.2 mg/kg (to a maximum dose of 5 mg), orally administered by the day surgery nurse in the day surgery holding area prior to surgery. |
Participants will receive oxybutynin 0.2 mg/kg (to a maximum dose of 5 mg), orally administered by the day surgery nurse in the day surgery holding area prior to surgery. |
|
安慰剂比较:Preoperative Placebo
Participants will receive a matching placebo tablet, orally administered by the day surgery nurse in the day surgery holding area prior to surgery. |
Participants will receive a matching placebo tablet, orally administered by the day surgery nurse in the day surgery holding area prior to surgery. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Total Cumulative Postoperative Opioid Consumption (MME/kg)
大体时间:From the end of surgery through 6 hours postoperatively
|
Total cumulative morphine milligram equivalents per kilogram (MME/kg) administered within 6 hours after surgery |
From the end of surgery through 6 hours postoperatively
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of Participants Receiving Postoperative Opioids
大体时间:From the end of surgery through 6 hours postoperatively
|
Whether any opioid medication was administered within 6 hours after surgery (yes/no) |
From the end of surgery through 6 hours postoperatively
|
|
Postoperative Pain Scores (NRS/FLACC)
大体时间:At 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 6 hours following postoperative removal of the laryngeal mask airway or endotracheal tube
|
Pain assessed using age-appropriate validated scales: the Numeric Rating Scale (NRS; 0-10) or the Face, Legs, Activity, Cry, Consolability (FLACC; 0-10) scale. Higher scores indicate greater pain. |
At 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 6 hours following postoperative removal of the laryngeal mask airway or endotracheal tube
|
|
Proportion of Participants Receiving Postoperative Rescue Oxybutynin
大体时间:From the end of surgery through 6 hours postoperatively
|
Whether oxybutynin was administered as needed (PRN) within 6 hours after surgery (yes/no). |
From the end of surgery through 6 hours postoperatively
|
|
Total Cumulative Postoperative Oxybutynin Consumption (mg/kg)
大体时间:From the end of surgery through 6 hours postoperatively
|
Total cumulative dose of oxybutynin administered per kilogram of body weight during the first 6 hours after surgery. |
From the end of surgery through 6 hours postoperatively
|
|
Incidence of Adverse Events
大体时间:From preoperative study medication administration through postoperative discharge
|
Occurrence of adverse events, including dry mouth, flushing, tachycardia, agitation, sedation, and urinary retention. |
From preoperative study medication administration through postoperative discharge
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- REB26-1464
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.